Forum partners

Swixx Group is one of the largest commercialization platforms representing the portfolio of pharmaceutical companies in those markets in which they choose not to enter or decide to exit.

Swixx Group of companies and affiliates operates across multiple countries in Central and Eastern Europe, Greece, Eurasia and several CIS countries, the Middle East and Latin America.

With more than 1,600 employees and sales which exceeded 1.1 billion Euros in 2024, the company is one of the fastest-growing independent commercialization platforms for biopharma globally.

Swixx has gathered outstanding rare disease, oncology-hematology, specialty, vaccines and self-medication talent under one roof.

Pharmasyntez Group is one of the leading Russian biopharmaceutical companies operating across various healthcare sectors, including research, production, manufacturing, and distribution of socially significant pharmaceuticals, innovative therapies, and active pharmaceutical ingredients. Pharmasyntez Group operates eight high-tech manufacturing facilities across Russia: in Ussuriysk, Irkutsk, Bratsk, Tyumen, St. Petersburg, Moscow, Kaluga. The annual production volume surpasses 100 million packages. As of 2025, the consolidated revenue of the Pharmasyntez Group reached 50,5 billion rubles. The staff exceeds 6,000 employees. Pharmasyntez develops and manufactures modern pharmaceuticals for a wide range of medical fields, including oncology, hematology, endocrinology, immunology, and cardiology. The company develops and produces pharmaceuticals for orphan diseases, hormonal disorders, infections, autoimmune conditions, cardiovascular diseases, and psychoneurological disorders. The company's portfolio covers therapies for diabetes, tuberculosis, hepatitis, HIV infection, COVID-19, chronic kidney insufficiency, and parenteral nutrition to support patients in critical conditions. Pharmasyntez encompasses one of Russia's largest R&D centers for biotechnological drugs. The company's ongoing research and development endeavors are paving the way for the next generation of innovative therapies for the fields of oncohematology, gynecology, and antiviral treatment. The product portfolio includes over 320 pharmaceutical products. Over 77% of the products manufactured are included in the List of Vital and Essential Drugs (VEDs). Pharmasyntez is the largest investor in the Russian pharmaceutical industry. To date, the company has invested more than 25 billion rubles in the expansion of production facilities and the development of new products.

GEROPHARM is an international producer of biotechnology products specializing in neurology, endocrinology, ophthalmology, gynecology, and urology. Its’ portfolio includes 40 original medicines and generics. GEROPHARM tops the Russian insulin market and is among the top 10 insulin manufacturers in the world. The Company runs all production stages at its own facilities in Russia by GxP standards. In 2023 GEROPHARM registered Semavic®, Russia's first Ozempic® analog, and in 2025 presented Mounjaro analog – Sejaro®. Medicinal products of the Company are represented in 14 countries.

Petrovax Pharm is a Russian company of company of novel biopharmaceutical practices, actively investing in scientific research and development.

The product portfolio includes original pharmaceutical products and vaccines, biotech drugs, and branded generics. The in-house R&D center for pre-clinical studies supports a full cycle of drug development.

The company's complex manufacturing for APIs and finished dosage forms is located in the Moscow region and operates in full compliance with the EAEU and EU GMP standards.

Petrovax’s development strategy focuses on providing patients with in-demand vaccines and drugs for the prevention and treatment of infectious, oncological, and orphan diseases.

Petrovax is implementing international projects with leading pharmaceutical companies: Pfizer, Abbott, ISU ABXIS, Adimmune, Hengrui. The company is one of the largest Russian exporters of original medicines and vaccines to the countries of the EAEU and the EU.

Our mission: Expanding access to cutting-edge therapies.

The primary activity of the ARPM is aimed at representing and protecting the professional interests of its members with the goal of developing a modern Russian pharmaceutical industry capable of ensuring the strategic independence of the Russian Federation in meeting the needs of citizens for high-quality and effective medicines.

IRWIN supplies medicinal products, medical equipment and medical devices for the needs of the Russian healthcare system.

IRWIN belongs to the PharmEco Group. There are over 12,000 items its portfolio, including medicinal products for social programs for prevention and treatment of cancer, diabetes, tuberculosis, hepatitis A and B, HIV infection. The company’s warehouse with the area of 10,500 sq. m is located in Podolsk (Moscow Region).

IRWIN is ranked second among suppliers of the budget market (according to IQVIA) and carries out its activities in all constituent entities of the Russian Federation relying on its modern and well-established GSP and GDP compliant logistics system.

Apart from distribution, IRWIN provides a full range of professional customs, logistic and warehousing services to pharmaceutical manufacturers, distributors and pharmacy chains.